Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Dave Yenne who wrote (504)	1/2/1998 8:43:00 PM
From: Dauntless	Read Replies (1) \| Respond to of 834

No problem - glad to have you join the thread. I don't know about an oral version of Novastan - it's got a pretty short half-life & that's a desirable feature. I'll try to find out. We have some M.D.'s here - any opinions??

To: Dave Yenne who wrote (504)	1/3/1998 5:22:00 PM
From: Ken Crooks	Read Replies (1) \| Respond to of 834

Dave, I think you're referring to the ETA med research. Excerpt: HOUSTON,TX, Thursday, December 11, 1997--HOUSTON -- Texas Biotechnology Corporation (Amex:TXB) today announced the completion of a Phase I study for an oral formulation of TBC11251, its small molecule endothelin-A (ETA) receptor antagonist. ---------- I'm not sure that an oral version of Novastan would have any practical application; sure haven't heard anything about it. Go to the tbc.com website for more info